AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04478071
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo once daily for 14 days.
Trial: NCT00610350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
Trial: NCT01031589
Drug: TMC278 (Rilpivirine) LA; Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00397761
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03960411
Drug: Doxycycline 100Mg Capsule
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline capsule
Trial: NCT03960411
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured to mimic doxycycline 100 mg capsule
Trial: NCT01160003
Drug: GW870086X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
Trial: NCT01608698
Drug: 30 mcg ethinylestradiol/2 mg chlormadinone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
Trial: NCT01608698
Drug: 30 mcg ethinylestradiol/3 mg drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
Trial: NCT05368545
Drug: High intensity lipid lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two different regimens of drugs with different effects on LDL lowering
Trial: NCT02592720
Drug: cocktail
RxNorm normalized name: Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
Trial: NCT02851797
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
Trial: NCT01160003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
Trial: NCT03587428
Drug: Zinc-A toothpaste
RxNorm normalized name: monofluorophosphate / potassium nitrate / zinc citrate Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Trial: NCT03587428
Drug: Zinc-B toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Trial: NCT03861416
Drug: L-arginine 1.4% 500 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
Trial: NCT03861416
Drug: L-arginine 1.4% 250 ml + placebo 250 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
Trial: NCT03861416
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
Trial: NCT02775591
Drug: DA-9701 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill manufactured to mask DA-9701 30mg Tablet
Trial: NCT03402204
Drug: Simvastatin 10 mg
RxNorm normalized name: simvastatin 10 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.
Trial: NCT03402204
Drug: Simvastatin 40 mg
RxNorm normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.
Trial: NCT01208961
Drug: Epanova (4 g) and Lovaza (4 g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
Trial: NCT01208961
Drug: Lovaza (4 g) and Epanova (4 g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
Trial: NCT02483156
Drug: Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
Trial: NCT00061815
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 IV
Trial: NCT01639339
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy
Trial: NCT01453205
Drug: MEDI-551 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Trial: NCT01453205
Drug: MEDI-551 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Trial: NCT00920387
Drug: 200 mcg LSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
Trial: NCT00920387
Drug: 20 mcg LSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
Trial: NCT02153502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules administered twice a day over a 10-week period
Trial: NCT02662283
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
Trial: NCT02407340
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
Trial: NCT01996696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo TID x 30-36 months
Trial: NCT03475706
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 12 weeks.
Trial: NCT02320435
Drug: Other Combination Anti-Cancer Therapies
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Trial: NCT04894877
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Trial: NCT02650804
Drug: BPM31510 Nanosuspension Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02633163
Drug: Placebo Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
Trial: NCT02251912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
Trial: NCT04890873
Drug: ERX1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
Trial: NCT04890873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A suspension containing magnesium hydroxide carbonate in polysorbate
Trial: NCT03611699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler
Trial: NCT02583685
Drug: PR4 + LDV/SOF + ASV 4 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Trial: NCT02583685
Drug: PR4 + LDV/SOF + SMV 4 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Trial: NCT02583685
Drug: PR4 + LDV/SOF + ASV 6 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Trial: NCT02583685
Drug: PR4 + LDV/SOF + SMV 6 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Trial: NCT02583685
Drug: PR4 + LDV/SOF + ASV 8 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Trial: NCT02583685
Drug: PR4 + LDV/SOF + SMV 8 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Trial: NCT02583685
Drug: PR4 + LDV/SOF + ASV 12 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Trial: NCT02583685
Drug: PR4 + LDV/SOF + SMV 12 wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Trial: NCT03785054
Drug: HTL0014242
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
Trial: NCT03785054
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT00974220
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose, 50 mcg of nebulized fentanyl citrate
Trial: NCT04140500
Drug: RO7247669
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
Trial: NCT03670030
Drug: ABI-009
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
Trial: NCT03022097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
Trial: NCT03710421
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03306979
Drug: N Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
Trial: NCT02979093
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All women will receive a nasal spray containing a placebo solution.
Trial: NCT01946529
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
Trial: NCT01946529
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
Trial: NCT02525549
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02064010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, administered orally for 4 weeks
Trial: NCT04485585
Drug: BR9006-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose
Trial: NCT04485585
Drug: BR9006-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose
Trial: NCT01746979
Drug: Placebo (5 percent dextrose - D5W)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Trial: NCT00352846
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.
Trial: NCT01772524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03883919
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Standard of care drug
Trial: NCT04313400
Drug: 1.1% w/w AMTX-100 CF-part1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
Trial: NCT04313400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream manufactured to mimic AMTX-100 CF3
Trial: NCT04313400
Drug: 1.1% w/w AMTX-100 CF3-part2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
Trial: NCT02767089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
Trial: NCT02319616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded, daily application to one arm for a period of fourteen (14) days
Trial: NCT00441142
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
Trial: NCT01597765
Drug: curcuminoids, N-acetylcysteine, deferiprone and vitamin E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
Trial: NCT00606034
Drug: U-500 Insulin delivered by Omnipod (disposable insulin pump)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
Trial: NCT04630860
Drug: LY03003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine,extended-release microspheres
Trial: NCT02138409
Drug: Fentanyl Sublingual Spray (FSS)
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
Trial: NCT02138409
Drug: Placebo Sublingual Spray (PSS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
Trial: NCT02643563
Drug: Bupivacaine 0.5% + epinephrine 1:200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
Trial: NCT02677207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Trial: NCT05149651
Drug: Totalfill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.